PRF1 and neoplasm: All 58 responder patients were CTL true (positive for five cytotoxic T lymphocyte markers, including CD8A, CD8B, GZMA, GZMB, and PRF1), indicating that the immune response to tumor T cell infiltration is highly consistent; that is, patients with high T cell infiltration have a high probability of responding to immunotherapy.